<DOC>
	<DOCNO>NCT02278783</DOCNO>
	<brief_summary>This non-blinded , single arm study test efficacy Regorafenib patient recurrent ovarian , primary peritoneal , fallopian tube cancer .</brief_summary>
	<brief_title>Phase 2 Trial Regorafenib Patients With Recurrent Ovarian , Primary Peritoneal Fallopian Tube Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>Age great equal 18 year . Life expectancy least 12 week ( 3 month ) . Diagnosis recurrent epithelial ovarian , primary peritoneal fallopian tube cancer . Histologic cytologic confirmation original primary tumor require . Patients must measurable disease define least one lesion accurately measure least one dimension long diameter ( LD ) great equal 10 mm use CT , MRI , caliper measurement great equal 20 mm xray . Patients must least one target lesion use assess response protocol define RECIST 1.1 . Prior therapy : Patients must least one prior platinumbased chemotherapeutic regimen management primary disease contain Carboplatin , Cisplatin , another organoplatinum compound . This initial treatment may include intraperitoneal therapy , consolidation , noncytotoxic agent ( include antiangiogenesis agent ) extend therapy ( i.e . maintenance therapy ) administer surgical nonsurgical assessment . Patients allow previously receive , require receive , one two additional cytotoxic regimens management recurrent disease . Patients receive one prior cytotoxic regimen ( platinum base regimen management primary disease ) , must platinumfree interval least 6 month . Patients must receive noncytotoxic therapy management recurrent persistent disease , except hormonal base therapy allow . Patients allow previously receive , require receive noncytotoxic therapy part primary treatment regimen . ECOG score 01 . Adequate bone marrow , liver renal function Patients progress initial platinumbased therapy upfront setting , persistent disease initial platinumbased therapy , recurrence le 6 month adjuvant chemotherapy exclude . Major surgical procedure significant traumatic injury within 28 day start study medication . Patients receive wide field radiotherapy less equal 4 week limited field radiation palliation less equal 2 week prior start study drug recover side effect therapy Patients receive continuous intermittent small molecule therapeutic ( exclude monoclonal antibody ) great equal 5 effective halflives prior start study drug recover side effect therapy . Patients receive chemotherapy target anticancer therapy great equal 4 week ( 6 week nitrosourea , antibody mitomycinC , 1 week hormone therapy ) prior start study drug recover side effect therapy . Active concurrent primary malignancy prior malignancy occur within 3 year ( except cervical carcinoma insitu , treat basal cell carcinoma , superficial bladder tumor . Use investigational drug , biologics , device within 28 day prior study enrollment . Prior use regorafenib . Strong inducer inhibitor CYP3A4 therapeutic anticoagulation VitaminK antagonist ( e.g . warfarin ) heparins heparinoids Women pregnant breastfeeding . Uncontrolled hypertension define systolic pressure great equal 140 mmHg diastolic pressure great equal 90 mmHg despite optimal medical management . Human immunodeficiency virus ( HIV ) positive diagnosis CD4 count &lt; 100 mm3 detectable viral load within past 3 month , receive combination antiretroviral therapy . Active clinically significant cardiac disease Evidence history bleed diathesis coagulopathy Any hemorrhage bleeding event â‰¥ NCI CTCAE v4.0 Grade 3 within 4 week prior start study medication . Subjects thrombotic , embolic , venous , arterial event , cerebrovascular accident ( include transient ischemic attack ) deep vein thrombosis pulmonary embolism within 6 month start study treatment . Patients pheochromocytoma Symptomatic metastatic brain meningeal tumor . Ongoing infection Presence nonhealing wound , nonhealing ulcer , bone fracture Patient 's history kidney disease persistent proteinuria must less Grade 3 proteinuria per NCI CTCAE v4.0 screening . Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g . active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>